<DOC>
	<DOCNO>NCT01170429</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety procaterol hydrochloride inhale glucocorticoid treatment patient cough variant asthma ( CVA ) .</brief_summary>
	<brief_title>Efficacy Safety Study Procaterol Hydrochloride Treat Patients With Cough Variant Asthma ( CVA )</brief_title>
	<detailed_description>This 8-week , double-blind , randomize , placebo-controlled study , patient CVA randomize experimental placebo control group . During screen period , eligible patient evaluate cough symptom score LCQ life quality score . After 4 8 week treatment , patient evaluate cough symptom score LCQ life quality score respectively . Adverse event also capture every visit .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Cough</mesh_term>
	<mesh_term>Procaterol</mesh_term>
	<criteria>male female patients,1875 year old ; cough last 3 week ; dry cough slight white mucous phlegm ; cough main clinical symptom symptom ; without wheeze fever ; without history upper respiratory tract infection within recent two month ; nonsmoking givingup smoke two year ; without rale lung ; obvious abnormality chest Xray ; bronchial provocation test : positive . patient chronic pulmonary disease ; patient allergic ß2 receptor agonist ; patient take ß2 receptor agonist long time ; severe heart , renal hepatic disease ; unable comply protocol ; pregnant , breast feeding , childbearing potential woman ; patient improper trial accord investigator ' judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Cough Variant Asthma</keyword>
	<keyword>Procaterol Hydrochloride</keyword>
</DOC>